Rome, Nov 6. (Adnkronos Health) – “We are very pleased to share the contribution we offer to Italian GDP: an investment of 718 million euros. Particularly significant is the multiplier effect: every euro Roche generates translates into 2.8 euros for the overall economic system. Similarly, we observe an employment multiplier: for every employee hired by Roche, 3.2 are generated in the Italian economy as a whole. We need to move from a vision of healthcare understood as a cost to a concept that recognizes it as an engine for the Italian economy. We see positive signs in the budget law. We hope that these signs will translate into structural reforms, such as overcoming the ‘payback’ mechanism, greater coherence in the regulatory framework – to accelerate recruitment in clinical studies and investments – and reforms that ensure timely access to therapies for patients in Italy.” So said Amy VanBuskirk, General Manager of Roche Pharma in Italy, speaking in Rome at the meeting ‘The Impact of Roche and the Value of Biotech: the sector as an engine of development and growth for Italy’.
The event was an opportunity to present the second edition of the Roche Impact Study in Italy, carried out with the methodological support of PwC Italy. During the conference, two awards were officially presented to the company: the ‘Cnel Seal’ for good participatory practices of workers and the 2026 Gender Equality award from Assolombarda, testifying to a company reality where over 54% of the workforce is female (with certified absence of gender pay gap Uni/PdR 125) and 30% is represented by under 40s.